Natural tissue scaffolds as tissue fillers
View Patent ↗Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.
1. A tissue filler, comprising:
an acellular tissue matrix having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for two weeks as was observed prior to implantation; and
at least one of exogenous hyaluronic acid (HA) and exogenous decorin on a surface of the acellular tissue matrix at a concentration which reduces an inflammatory response or fibrosis when the tissue filler is implanted in a body as compared to the same tissue filler not comprising hyaluronic acid or decorin.
2. The tissue filler of claim 1 , wherein a concentration of HA on the acellular tissue matrix is between approximately 0.5 mg and approximately 5.0 mg per gram of tissue filler.
3. The tissue filler of claim 1 , further comprising at least one growth factor.
4. The tissue filler of claim 3 , wherein the at least one growth factor is selected from at least one of FGF, VEGF, PDGF, Angiopoitin-2, or Follistatin.
5. The tissue filler of claim 1 , wherein the tissue filler has been treated to reduce a bioburden.
6. The tissue filler of claim 1 , further comprising an antimicrobial agent.
7. The tissue filler of claim 6 , wherein the antimicrobial agent includes at least one of chlorhexidine (CHX) and silver.
8. The tissue filler of claim 7 , wherein the CHX has a concentration between approximately 0.1 mg and approximately 3.0 mg per gram of tissue filler.
9. The tissue filler of claim 8 , wherein the silver has a concentration between approximately 0.1 mg and approximately 1.0 mg per gram of tissue filler.
10. The tissue filler of claim 1 , wherein the tissue filler is capable of being compressed up to approximately ⅔ of its length or width.
11. The tissue filler of claim 10 , wherein the tissue filler is capable of returning to its original dimensions after release of compression.
12. The tissue filler of claim 1 , wherein a concentration of decorin on the acellular tissue matrix is between approximately 0.3 mg and approximately 1.0 mg per gram of tissue filler.
13. The tissue filler of claim 1 , wherein the acellular tissue matrix comprises a dermal matrix.
14. A method of treating a tissue site, comprising:
selecting a tissue site; and
implanting the tissue filler of claim 1 in the tissue site.
15. A tissue filler, comprising:
an acellular tissue matrix having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for two weeks as was observed prior to implantation; and
exogenous hyaluronic acid (HA) on a surface of the acellular tissue matrix at a concentration which reduces an inflammatory response or fibrosis when the tissue filler is implanted in a body as compared to the same tissue filler not comprising hyaluronic acid.
16. The tissue filler of claim 15 , wherein the acellular tissue matrix comprises a dermal matrix.
17. A tissue filler, comprising:
an acellular tissue matrix having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for two weeks as was observed prior to implantation; and
exogenous decorin on a surface of the acellular tissue matrix at a concentration which reduces an inflammatory response or fibrosis when the tissue filler is implanted in a body as compared to the same tissue filler not comprising decorin.
18. The tissue filler of claim 17 , wherein the acellular tissue matrix comprises a dermal matrix.